UK markets open in 6 hours 9 minutes
NIKKEI 225
38,170.97 -234.69 (-0.61%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.14 -0.79 (-0.96%) GOLD FUTURES
2,299.40 -3.50 (-0.15%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,268.99 -3,339.30 (-6.47%)
Merck & Co., Inc. (6MK.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 02:20PM CEST
| Previous close | 122.20 |
| Open | 121.40 |
| Bid | 121.00 x 100000 |
| Ask | 121.00 x 100000 |
| Day's range | 120.80 - 121.40 |
| 52-week range | 90.70 - 123.20 |
| Volume | |
| Avg. volume | 338 |
| Market cap | 307.003B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.29 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.84 (2.33%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
- Business Wire
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).
© 2024 Yahoo. All rights reserved.